This article is more than 5 years old. Information may no longer be current.
VIDEO: Developing targeted therapy for sarcoma remains a challenge
Click Here to Manage Email Alerts
CHICAGO — Gary K. Schwartz, MD, chief of hematology and oncology at NewYork-Presbyterian/Columbia University Medical Center, discusses research that evaluates treatments for sarcoma that target receptor tyrosine kinases at the ASCO Annual Meeting.
He presents his takeaways from two clinical trials that evaluated new uses of already-approved agents pazopanib (Votrient, Novartis) — approved to treat patients with metastatic sarcoma who failed prior chemotherapy — and regorafenib (Stivarga, Bayer), approved for the treatment of advanced gastrointestinal stromal tumors that cannot be surgically removed and have progressed despite treatment with other FDA–approved agents.
Schwartz also discusses a trial that evaluates the novel agent anlotinib (Advenchen Laboratories and Jiangsu Chia-tai Tianqing Pharmaceutical), which is under investigation in China for the treatment of various sarcoma subtypes.
“The challenge will be developing drugs that target not just one or two receptors, but multiple receptors, and I think this is an area for future clinical and science research and we will be seeing more efforts in this area,” Schwartz said.